ArriVent BioPharma, Inc.
AVBP
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.4B
$30.95
▼ -0.26%
P/E
-8.41
Mkt Cap
$1.4B
52-Wk Range
$17.00–$35.83
52-Week Range
$17.00 - $35.83
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 53.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Selective EGFR inhibitor technology with potential for improved tolerability profile
- Phase 3 clinical trial advancement demonstrating clinical validation
- Strategic partnerships with established biotech firms accelerating development
- Focused pipeline approach targeting high-prevalence cancer indications
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Furmonertinib Phase 3 trial completion and potential FDA approval pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+1.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AVBP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 12, 2026
Reported EPS of -$1.05 vs -$0.99 consensus (-6.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-6.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 17, 2026
vs Industry
How AVBP stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related